This application relates to PCT/US2006/008688 filed Mar. 10, 2006 published as WO 2006/099191 A2, U.S. Ser. No. 11/908,071 filed Sep. 7, 2007, and U.S. Ser. No. 61/338,303 filed Feb. 16, 2010 all of which are hereby incorporated by reference herein in their entireties.
1. Field of the Invention
This invention relates broadly to immunoassay devices and the methods for their use. More particularly, this invention relates to chromatographic rapid test strips for detection of a ligand in a body fluid.
2. State of the Art
Many types of ligand-receptor assays have been used to detect the presence of various substances, often generally called ligands, in body fluids such as blood, urine, or saliva. These assays involve antigen antibody reactions, synthetic conjugates comprising radioactive, enzymatic, fluorescent, or visually observable polystyrene or metal sol tags, and specially designed reactor chambers. In all these assays, there is a receptor, e.g., an antibody, which is specific for the selected ligand or antigen, and a means for detecting the presence, and in some cases the amount, of the ligand-receptor reaction product. Some tests are designed to make a quantitative determination, but in many circumstances all that is required is a positive/negative qualitative indication. Examples of such qualitative assays include blood typing, most types of urinalysis, pregnancy tests, and AIDS tests. For these tests, a visually observable indicator such as the presence of agglutination or a color change is preferred.
Even the qualitative assays must be very sensitive because of the often small concentration of the ligand of interest in the test fluid. False positives can also be troublesome, particularly with agglutination and other rapid detection methods such as dipstick and color change tests. Because of these problems, so-called “sandwich” assays and other sensitive detection mechanisms which use metal sols or other types of colored particles have been developed.
In a “sandwich” assay, a target analyte such as an antigen is “sandwiched” between a labeled antibody and an antibody immobilized onto a solid support. The assay is read by observing the presence and/or amount of bound antigen-labeled antibody complex. In a “competition” immunoassay, antibody bound to a solid surface is contacted with a sample containing an unknown quantity of antigen analyte and with labeled antigen of the same type. The amount of labeled antigen bound on the solid surface is then determined to provide an indirect measure of the amount of antigen analyte in the sample.
Because these and other assays can detect both antibodies and antigens, they are generally referred to as immunochemical ligand-receptor assays or simply immunoassays.
Solid phase immunoassay devices, whether of the sandwich or competition type, provide sensitive detection of an analyte in a biological fluid sample such as blood, urine, or saliva. Solid phase immunoassay devices incorporate a solid support to which one member of a ligand-receptor pair, usually an antibody, antigen, or hapten, is bound. Common early forms of solid supports were plates, tubes, or beads of polystyrene which were well known from the fields of radioimmunoassay and enzyme immunoassay. In the last decade, a number of porous materials such as nylon, nitrocellulose, cellulose acetate, glass fibers, and other porous polymers have been employed as solid supports.
A number of self-contained immunoassay kits using porous materials as solid phase carriers of immunochemical components such as antigens, haptens, or antibodies have been described. These kits are usually dipstick, flow-through, or migratory in design.
In the more common forms of dipstick assays, as typified by home pregnancy and ovulation detection kits, immunochemical components such as antibodies are bound to a solid phase. The assay device is “dipped” for incubation into a sample suspected of containing unknown antigen analyte. Enzyme-labeled antibody is then added, either simultaneously or after an incubation period. The device is then washed and inserted into a second solution containing a substrate for the enzyme. The enzyme-label, if present, interacts with the substrate, causing the formation of colored products which either deposit as a precipitate onto the solid phase or produce a visible color change in the substrate solution.
Flow-through type immunoassay devices were designed to obviate the need for extensive incubation and cumbersome washing steps associated with dipstick assays. Valkirs et al., U.S. Pat. No. 4,632,901, disclose a device comprising antibody (specific to a target antigen analyte) bound to a porous membrane or filter to which is added a liquid sample. As the liquid flows through the membrane, target analyte binds to the antibody. The addition of sample is followed by addition of labeled antibody. The visual detection of labeled antibody provides an indication of the presence of target antigen analyte in the sample.
Korom et al., EP-A 0 299 359, discloses a variation in the flow-through device in which the labeled antibody is incorporated into a membrane which acts as a reagent delivery system.
The requirement of multiple addition and washing steps with dipstick and flow-through type immunoassay devices increases the likelihood that minimally trained personnel and home users will obtain erroneous assay results.
In migration type assays, a membrane is impregnated with the reagents needed to perform the assay. An analyte detection zone is provided in which labeled analyte is bound and assay indicia is read. See, for example, Tom et al., U.S. Pat. No. 4,366,241, and Zuk, et al. U.S. Pat. No. 4,596,275. The sensitivity of migration type assays is frequently reduced, however, by the presence or formation in the sample of undesirable solid components which block the passage of labeled analyte to the detection zone. Assay sensitivity also declines when migration assay devices are flooded with too much liquid sample.
Migration assay devices usually incorporate within them reagents which have been attached to colored labels (i.e., conjugates), thereby permitting visible detection of the assay results without addition of further substances. See, for example, Bernstein, U.S. Pat. No. 4,770,853. Among such labels are gold sol particles such as those described by Leuvering in U.S. Pat. No. 4,313,734, dye sol particles such as described in U.S. Pat. No. 4,373,932 by Gribnau et al., dyed latex such as described by May et al., WO 88/08534, and dyes encapsulated in liposomes by Campbell et al., U.S. Pat. No. 4,703,017. These colored labels are generally limited in terms of the immobilization methods which are suitable. Moreover, they require a relatively large amount of ligand molecule and can involve expensive reagents, thereby adding to the cost.
The “Related Applications” set forth above overcome many deficiencies of the prior art by providing “dual path” immunoassays which are highly sensitive, extremely reliable, accurate and inexpensive rapid detection devices. Generally, the dual path immunoassays include a first sorbent material having a first location for receiving a buffer solution (in the case of a dry conjugate system) or a conjugate solution (in the case of a liquid conjugate system) with the first sorbent material defining a first horizontal flow path, a second sorbent material having a second location for receiving a sample with the second sorbent material defining a second horizontal flow path distinct from the first flow path, and a test line or test site with immobilized antigens or antibodies or other ligand binding molecules such as aptamers, nucleic acids, etc. located in a test zone at a junction of the first and second sorbent materials.
Various types of samples are effectively tested using the duel path immunoassays, including but not limited to whole blood, blood serum, urine, sputum, saliva, and feces. For most samples it is common to utilize buffer solution to cause the sample to flow along the second sorbent material. Thus, one method of using a dual path immunoassays involves (1) depositing a sample at the (second) location for receiving the sample, (2) depositing buffer solution at the same location of the sample, (3) waiting a period of time sufficient to permit the sample to reach the test zone, (4) after waiting, depositing additional buffer solution at the (first) location for receiving the buffer solution such that the additional buffer solution causes the conjugate to flow to the test zone, and (5) inspecting the test zone to determine whether the test is positive or negative.
According to one aspect of the invention, a rapid detection dual path immunoassay device is provided that requires fewer steps to use than the previous dual path immunoassay devices.
According to another aspect of the invention, a dual path immunoassay device is provided that is simple to use and provides accurate results.
In one embodiment, a dry conjugate dual path immunoassay device system is provided and includes a test cell with a first location for receiving a sample and a second location for receiving a buffer solution. A first sorbent material is provided for directing a horizontal flow path for the sample. Means are provided for dividing the buffer solution received at the second location such that some of the buffer solution is directed to the first sorbent material which directs the sample, and some of the buffer solution is directed to a second sorbent material. In one embodiment, the second sorbent material takes an elongated path (e.g., curved, angled, or tortuous path) to the test zone which is located at the junction of the elongated path of the second sorbent material with the first sorbent material. In another embodiment, the second sorbent material is provided with a delay element along its length. In yet another embodiment, second and third sorbent materials are provided with the third sorbent material initially receiving the buffer solution and having a slower flow characteristic than the first sorbent material, and the second sorbent material in contact with the third sorbent material and forwarding the buffer solution to the test zone which is located at the junction of the second sorbent material and the first sorbent material. Regardless, conjugate is provided at a location along the second sorbent material. Preferably, the flow path provided by the first sorbent material is a direct path to the test zone. The test zone preferably includes one or more test lines or test sites with immobilized antigens or antibodies or other ligand binding molecules such as aptamers, nucleic acids, etc.
Where the test cell of the invention is provided in a housing, the housing is provided with a first opening adjacent the first location and a second opening adjacent the second location. A viewing window is provided in the housing above the test line.
Various means for dividing the buffer solution received at the second location are provided. A first means for dividing the buffer solution is a wedge element (V-shaped or triangular in cross-section) located at the location for receiving the buffer solution (e.g., an opening in a housing), where the apex of the V or triangle is directed upward. As drops of buffer solution are dropped into the buffer receiving opening, the apex divides the drops into two streams. The first stream is directed to the first sorbent material. The second stream is directed to the second elongated path sorbent material.
A second means for dividing the buffer solution received at the second location is a flow control material which is chosen to permit buffer to flow but which is resistant to receiving sample. The flow control material is coupled to both the first and second sorbent materials.
A third means for dividing the buffer solution received at the second location is an arrangement where the second location is an opening in a housing sized to receive the nib of a buffer dispenser, and a vertical wall recessed in the housing opening is provided to divide the buffer solution. Preferably, the first sorbent material is provided on one side of the vertical wall, and the second sorbent material is provided on the other side of the vertical wall.
According to one aspect of the invention, the means for dividing the buffer solution may be arranged so that approximately half of the buffer solution is directed toward the first sorbent material and the other half of the buffer solution is directed toward the second sorbent material.
According to another aspect of the invention, the means for dividing the buffer solution may be arranged so that a desired first proportion of the buffer solution is directed toward the first sorbent material and a desired different second proportion of the buffer solution is directed toward the second sorbent material.
In one embodiment, the locations for receiving the sample and the buffer solution are near or adjacent each other.
In the preferred embodiment of the invention, the first sorbent material and second sorbent material are separate pieces which overlie one another at the test site junction, and the test line is printed on one or both of the sorbent materials at the junction. The systems of the invention preferably also include a control line or site which may be seen from the viewing window.
According to one aspect of the invention, a test cell as summarized above may be used by (1) depositing a sample at the (first) location for receiving the sample, (2) depositing buffer solution at the (second) location for receiving the buffer solution, and (3) after a desired period of time, inspecting the test zone to determine whether the test is positive or negative. It is noted that sufficient buffer is deposited at the second location to cause the sample to move along the first sorbent material to the test zone, as well as to traverse the path of the second (and where provided, third) sorbent material and cause the conjugate to move to the test zone. Because of the arrangement of the first sorbent material as well as the second (and where provided, third) sorbent material, the sample is brought to the test zone in advance of the conjugate.
In one embodiment of the invention, the materials, thicknesses and lengths of the first and second sorbent materials are chosen to adjust the timing regarding the sample and conjugate reaching the test site.
In a fourth generation assay, two paths are provided for directing sample to two test zones, and two elongated paths are provided for carrying buffer and conjugate to the test zones. A first test zone is provided at the intersection of one of the elongated paths with one of the two sample paths, and a second test zone is provided at an intersection of the other elongated path and the second of the sample paths. In the fourth generation assay, one of the test zones may test for antigens in the sample while the other of the test zones may test for antibodies in the sample.
Additional objects and advantages of the invention will become apparent to those skilled in the art upon reference to the detailed description taken in conjunction with the provided figures.
a is a schematic view of a third embodiment of the invention.
b is a schematic view of an alternative third embodiment of the invention.
a is a side view of the third embodiment of the buffer divider.
Before turning to the Figures, the previously incorporated applications are noted as providing examples of dual path immunoassay devices relevant to the present invention. In particular, many of the same elements described in the embodiments of the previously incorporated applications are utilized as the building blocks for the embodiments of the invention which are further described below. As a result, details of those elements are not further described, and attention may be paid to those applications for those details.
Turning now to
A second embodiment of a dry conjugate dual path immunoassay device system 1100 is seen in
Alternate third embodiments of a dry conjugate dual path immunoassay device system 1200a, 1200b are seen in
A fourth embodiment of a dry conjugate dual path immunoassay device system 1300 is seen in
A fifth embodiment of a dry conjugate dual path immunoassay device system 1400 is seen in
In the fourth and fifth embodiments, the third sorbent or bibulous material which has a slower flow characteristic relative to the first sorbent material may be a small pore membrane (e.g., nitrocellulose or nylon membrane having a pore size of 3 to 30 microns), glass fibers, or cellulose, polyester, rayon or other known synthetic materials. As will be appreciated by those skilled in the art, other materials could be utilized to control the speed of the buffer flow through the third sorbent material and thereby control arrival timing of the buffer with the conjugate at the test site relative to the arrival of the sample.
A sixth embodiment of a dry conjugate dual path immunoassay device system 1500 is seen in
In all the previous embodiments, where the test cell of the invention is provided in a housing, the housing is provided with a first opening adjacent the first location and a second opening adjacent the second location. A viewing window is provided in the housing above the test line. Where a control line is provided, the viewing window may extend over the test line and control line, or a separate viewing window may be provided over the control line.
In all of the previous embodiments, it is preferred that the locations for receiving the sample and the buffer solution are provided near or adjacent each other.
Turning now to
A second divider for the buffer solution received at the second location is shown in
A third divider 1601b for the buffer solution received at the second location is shown in
With respect to all of the above test cell embodiments and buffer divider embodiments, if desired, the buffer may be packaged as part of the test cell by providing a “buffer button” 1780 as seen in
According to one aspect of the invention, any of the test cells described above may be used by (1) depositing a sample at the (first) location for receiving the sample, (2) depositing a predetermined amount of buffer solution at the (second) location for receiving the buffer solution, and (3) after a desired period of time, inspecting the test zone(s) and where provided the control zone(s) to determine whether the test is positive or negative. It is noted that sufficient buffer is deposited at the second location to cause the sample to move along the first sorbent material to the test zone, as well as to traverse the path of the second (and where provided, third) sorbent material and cause the conjugate to move to the test zone. Because of the arrangement of the first sorbent material as well as the second (and where provided, third) sorbent material, the sample is brought to the test zone in advance of the conjugate. The step of depositing a sample may involve depositing blood, serum, spittum, feces, or other bodily fluid at the first location via a dropper, a swab, a loop or other depositing means known in the art. The step of depositing a predetermined amount of buffer solution may comprise utilizing a dropper, pressing a buffer button, or utilizing any other depositing means known in the art.
It will be appreciated that the materials, thicknesses and lengths of the first and second sorbent materials are chosen to adjust the timing regarding the sample and conjugate reaching the test site(s).
There have been described and illustrated herein several embodiments of immunoassays and methods of their use. While particular embodiments of the invention have been described, it is not intended that the invention be limited thereto, as it is intended that the invention be as broad in scope as the art will allow and that the specification be read likewise. For example, while the specification discusses ligand binding using antigen/antibody reactions, other ligand binding mechanisms such as aptamer binding, nucleic acid binding, enzymatic binding, etc. may also be used. Also while particular buffer dividers have been described which divide the buffer for the sample flow path and the conjugate flow path, it will be appreciated that other dividers could be utilized. Further, it should be appreciated that chemical agents such as sugar, BSA, detergent, etc., or biological agents (serum, antibody, antigen) may be added in one or both of the sorbent strips in order to delay or enhance flow rate for the buffer or for the buffer/sample solution. These modifications could be additionally utilized to enhance sensitivity or block non-specific binding for the assay. It will therefore be appreciated by those skilled in the art that yet other modifications could be made to the provided invention without deviating from its spirit and scope as claimed.
Number | Name | Date | Kind |
---|---|---|---|
3960488 | Giaever | Jun 1976 | A |
4041146 | Giaever | Aug 1977 | A |
4042335 | Clement | Aug 1977 | A |
4059405 | Sodickson et al. | Nov 1977 | A |
4094647 | Deutsch et al. | Jun 1978 | A |
4144306 | Figueras | Mar 1979 | A |
4235601 | Deutsch et al. | Nov 1980 | A |
4313734 | Leuvering | Feb 1982 | A |
4323536 | Columbus | Apr 1982 | A |
4361537 | Deutsch et al. | Nov 1982 | A |
4366241 | Tom et al. | Dec 1982 | A |
4373932 | Gribnau | Feb 1983 | A |
4522786 | Ebersole | Jun 1985 | A |
4532107 | Siddigi | Jul 1985 | A |
4588555 | Provonchee | May 1986 | A |
4595654 | Reckel et al. | Jun 1986 | A |
4632901 | Valkirs et al. | Dec 1986 | A |
4668619 | Greenquist et al. | May 1987 | A |
4703017 | Campbell et al. | Oct 1987 | A |
4740468 | Weng et al. | Apr 1988 | A |
4770853 | Bernstein | Sep 1988 | A |
4786595 | Arai et al. | Nov 1988 | A |
4826759 | Guire et al. | May 1989 | A |
4855240 | Rosenstein et al. | Aug 1989 | A |
4857453 | Ullman et al. | Aug 1989 | A |
4870003 | Kortright et al. | Sep 1989 | A |
4886742 | Kortright et al. | Dec 1989 | A |
4906439 | Grenner | Mar 1990 | A |
4912034 | Kalra et al. | Mar 1990 | A |
4920046 | McFarland et al. | Apr 1990 | A |
4943522 | Eisinger et al. | Jul 1990 | A |
4956275 | Zuk et al. | Sep 1990 | A |
4956302 | Gordon et al. | Sep 1990 | A |
4960691 | Gordon et al. | Oct 1990 | A |
4960710 | Lau | Oct 1990 | A |
4981785 | Nayak | Jan 1991 | A |
4981786 | Dafforn et al. | Jan 1991 | A |
5004584 | Rayman | Apr 1991 | A |
5006464 | Chu et al. | Apr 1991 | A |
5006474 | Horstman et al. | Apr 1991 | A |
5075077 | Durley, III et al. | Dec 1991 | A |
5087556 | Ertinghausen | Feb 1992 | A |
5091153 | Bachand | Feb 1992 | A |
5104793 | Buck | Apr 1992 | A |
5104811 | Berger et al. | Apr 1992 | A |
5110550 | Schlipfenbacher | May 1992 | A |
5132208 | Freitag et al. | Jul 1992 | A |
5137808 | Ullman et al. | Aug 1992 | A |
5147780 | Pouletty et al. | Sep 1992 | A |
5156952 | Litman et al. | Oct 1992 | A |
5162238 | Eikmeier et al. | Nov 1992 | A |
5169789 | Bernstein | Dec 1992 | A |
5173433 | Bachand | Dec 1992 | A |
5200321 | Kidwell | Apr 1993 | A |
5202268 | Kuhn et al. | Apr 1993 | A |
5215446 | Takahashi | Jun 1993 | A |
5217905 | Marchand et al. | Jun 1993 | A |
5219762 | Katamine et al. | Jun 1993 | A |
5223436 | Freitag et al. | Jun 1993 | A |
RE34312 | Geiger et al. | Jul 1993 | E |
5232835 | Litman et al. | Aug 1993 | A |
5238649 | Nason | Aug 1993 | A |
5240735 | Lau | Aug 1993 | A |
5244631 | Morikawa | Sep 1993 | A |
5244788 | Hubscher | Sep 1993 | A |
RE34405 | Gould et al. | Oct 1993 | E |
5252496 | Kang et al. | Oct 1993 | A |
5275785 | May et al. | Jan 1994 | A |
5281540 | Merkh et al. | Jan 1994 | A |
5296192 | Carroll et al. | Mar 1994 | A |
5300439 | Charlton | Apr 1994 | A |
5306623 | Kiser et al. | Apr 1994 | A |
5308775 | Donovan et al. | May 1994 | A |
5332548 | Moore | Jul 1994 | A |
5334502 | Sangha | Aug 1994 | A |
5338513 | Schlipfenbacher | Aug 1994 | A |
5340748 | Baugher et al. | Aug 1994 | A |
5356782 | Moorman et al. | Oct 1994 | A |
5362654 | Pouletty | Nov 1994 | A |
5369007 | Kidwell | Nov 1994 | A |
5384264 | Chen et al. | Jan 1995 | A |
5391478 | Greene et al. | Feb 1995 | A |
5399316 | Yamada | Mar 1995 | A |
5411858 | McGeeham et al. | May 1995 | A |
5418136 | Miller et al. | May 1995 | A |
5418142 | Kiser et al. | May 1995 | A |
5418167 | Matner et al. | May 1995 | A |
5424215 | Albarella et al. | Jun 1995 | A |
5424220 | Goerlach-Graw et al. | Jun 1995 | A |
5435970 | Mamenta et al. | Jul 1995 | A |
5451504 | Fitzpatrick et al. | Sep 1995 | A |
5468648 | Chandler | Nov 1995 | A |
5470713 | El Shami et al. | Nov 1995 | A |
5474902 | Uylen et al. | Dec 1995 | A |
5482830 | Bogart et al. | Jan 1996 | A |
5494830 | Hubscher | Feb 1996 | A |
5500350 | Baker et al. | Mar 1996 | A |
5501985 | Baugher et al. | Mar 1996 | A |
5514557 | Moghaddam | May 1996 | A |
5521102 | Boehringer et al. | May 1996 | A |
5532133 | Barnwell | Jul 1996 | A |
5541057 | Bogart et al. | Jul 1996 | A |
5550063 | Bogart | Aug 1996 | A |
5552272 | Bogart | Sep 1996 | A |
5558834 | Chu et al. | Sep 1996 | A |
5559041 | Kang et al. | Sep 1996 | A |
5567594 | Calenoff | Oct 1996 | A |
5571667 | Chu et al. | Nov 1996 | A |
5591645 | Rosenstein | Jan 1997 | A |
5602040 | May et al. | Feb 1997 | A |
5604110 | Baker et al. | Feb 1997 | A |
5607863 | Chandler | Mar 1997 | A |
5616467 | Olsen et al. | Apr 1997 | A |
5620845 | Gould et al. | Apr 1997 | A |
5622871 | May et al. | Apr 1997 | A |
5624809 | Skold et al. | Apr 1997 | A |
5629164 | Rivers | May 1997 | A |
5629214 | Crosby | May 1997 | A |
5639671 | Bogart et al. | Jun 1997 | A |
5641639 | Perry | Jun 1997 | A |
5648274 | Chandler | Jul 1997 | A |
5656503 | May et al. | Aug 1997 | A |
5658723 | Oberhardt | Aug 1997 | A |
5658801 | Poissant et al. | Aug 1997 | A |
5670381 | Jou et al. | Sep 1997 | A |
5686315 | Pronovost | Nov 1997 | A |
5695928 | Stewart et al. | Dec 1997 | A |
5695930 | Weinstein et al. | Dec 1997 | A |
5710005 | Rittenburg | Jan 1998 | A |
5714341 | Thieme et al. | Feb 1998 | A |
5714389 | Charlton et al. | Feb 1998 | A |
5723345 | Yamauchi et al. | Mar 1998 | A |
5726010 | Clark | Mar 1998 | A |
5728587 | Kang et al. | Mar 1998 | A |
5736188 | Alcock et al. | Apr 1998 | A |
5739041 | Nazareth et al. | Apr 1998 | A |
5743960 | Tisone | Apr 1998 | A |
5750333 | Clark | May 1998 | A |
5766961 | Pawlak et al. | Jun 1998 | A |
5766962 | Childs et al. | Jun 1998 | A |
5770460 | Pawlak et al. | Jun 1998 | A |
5773234 | Pronovost et al. | Jun 1998 | A |
5786220 | Pronovost et al. | Jul 1998 | A |
5807756 | Bauman et al. | Sep 1998 | A |
5814522 | Zimmer et al. | Sep 1998 | A |
5824268 | Bernstein et al. | Oct 1998 | A |
5827646 | Middeldorp et al. | Oct 1998 | A |
5846838 | Chandler | Dec 1998 | A |
5853670 | Bunce | Dec 1998 | A |
5861265 | Perry | Jan 1999 | A |
5869272 | Bogart et al. | Feb 1999 | A |
5869345 | Chandler | Feb 1999 | A |
5872713 | Douglas et al. | Feb 1999 | A |
5874216 | Mapes | Feb 1999 | A |
5877028 | Chandler et al. | Mar 1999 | A |
5879951 | Sy | Mar 1999 | A |
5885526 | Chu | Mar 1999 | A |
5885527 | Buechler | Mar 1999 | A |
5891650 | Godowski et al. | Apr 1999 | A |
5900379 | Noda et al. | May 1999 | A |
5902722 | Di Cesare et al. | May 1999 | A |
5912116 | Caldwell | Jun 1999 | A |
5922533 | Vallari et al. | Jul 1999 | A |
5922615 | Nowakowski et al. | Jul 1999 | A |
5935331 | Naka et al. | Aug 1999 | A |
5939252 | Lennon et al. | Aug 1999 | A |
5939272 | Buechler et al. | Aug 1999 | A |
5948695 | Douglas et al. | Sep 1999 | A |
5955377 | Maul et al. | Sep 1999 | A |
5958790 | Cerny | Sep 1999 | A |
5965458 | Kouvonen et al. | Oct 1999 | A |
5972720 | Nichtl et al. | Oct 1999 | A |
5976895 | Cipkowski | Nov 1999 | A |
5985675 | Charm et al. | Nov 1999 | A |
5989921 | Charlton et al. | Nov 1999 | A |
5998220 | Chandler | Dec 1999 | A |
5998221 | Malick et al. | Dec 1999 | A |
6008056 | Thieme | Dec 1999 | A |
6017767 | Chandler | Jan 2000 | A |
6027890 | Ness et al. | Feb 2000 | A |
6040195 | Carroll et al. | Mar 2000 | A |
6046013 | Tidey et al. | Apr 2000 | A |
6046057 | Nazareth et al. | Apr 2000 | A |
6057166 | Childs et al. | May 2000 | A |
6060326 | Frank et al. | May 2000 | A |
6063337 | Markart | May 2000 | A |
6087184 | Magginetti et al. | Jul 2000 | A |
6106732 | Johnston et al. | Aug 2000 | A |
6140134 | Rittenburg | Oct 2000 | A |
6140136 | Lee | Oct 2000 | A |
6168956 | Chandler | Jan 2001 | B1 |
6187268 | Albarella et al. | Feb 2001 | B1 |
6187598 | May et al. | Feb 2001 | B1 |
6194220 | Malick et al. | Feb 2001 | B1 |
6197494 | Oberhardt | Mar 2001 | B1 |
6221625 | Ashihara et al. | Apr 2001 | B1 |
6221678 | Chandler | Apr 2001 | B1 |
6224831 | Stafford et al. | May 2001 | B1 |
6228660 | May et al. | May 2001 | B1 |
6235464 | Henderson et al. | May 2001 | B1 |
6248598 | Bogema | Jun 2001 | B1 |
6258548 | Buck | Jul 2001 | B1 |
6271040 | Buechler | Aug 2001 | B1 |
6271045 | Douglas et al. | Aug 2001 | B1 |
6271046 | Chandler | Aug 2001 | B1 |
6277650 | Nazareth et al. | Aug 2001 | B1 |
6284550 | Carroll et al. | Sep 2001 | B1 |
6287875 | Geisberg | Sep 2001 | B1 |
6297020 | Brock | Oct 2001 | B1 |
6297060 | Nowakowski et al. | Oct 2001 | B1 |
6300142 | Andrewes et al. | Oct 2001 | B1 |
RE37437 | Friesen et al. | Nov 2001 | E |
6316205 | Guan et al. | Nov 2001 | B1 |
6316264 | Corey et al. | Nov 2001 | B1 |
6319676 | Nazareth et al. | Nov 2001 | B1 |
6326214 | Liu et al. | Dec 2001 | B1 |
6335205 | Bausback | Jan 2002 | B1 |
6352862 | Davis et al. | Mar 2002 | B1 |
6362008 | Kohn et al. | Mar 2002 | B1 |
6368875 | Geisberg | Apr 2002 | B1 |
6368876 | Huang et al. | Apr 2002 | B1 |
6372514 | Lee | Apr 2002 | B1 |
6372515 | Casterlin et al. | Apr 2002 | B1 |
6372516 | Sun | Apr 2002 | B1 |
6376195 | Mapes | Apr 2002 | B1 |
6399398 | Cunningham et al. | Jun 2002 | B1 |
6403383 | Casterlin et al. | Jun 2002 | B1 |
6403384 | Lea | Jun 2002 | B1 |
6406922 | Casterlin et al. | Jun 2002 | B2 |
6413473 | Bacon | Jul 2002 | B1 |
6413784 | Lundsgaard et al. | Jul 2002 | B1 |
6436722 | Clark et al. | Aug 2002 | B1 |
6455324 | Douglas | Sep 2002 | B1 |
6472226 | Barradine et al. | Oct 2002 | B1 |
6475805 | Charm et al. | Nov 2002 | B1 |
6485982 | Charlton | Nov 2002 | B1 |
6489129 | Faatz et al. | Dec 2002 | B1 |
6492127 | Goodell et al. | Dec 2002 | B2 |
6500629 | Cleaver et al. | Dec 2002 | B1 |
6502766 | Streutker et al. | Jan 2003 | B1 |
6503702 | Stewart | Jan 2003 | B1 |
6503722 | Valkirs | Jan 2003 | B1 |
6511814 | Carpenter | Jan 2003 | B1 |
6514769 | Lee | Feb 2003 | B2 |
6514773 | Klein et al. | Feb 2003 | B1 |
6528321 | Fitzgerald et al. | Mar 2003 | B1 |
6528322 | Carlsson et al. | Mar 2003 | B1 |
6528323 | Thayer et al. | Mar 2003 | B1 |
6528325 | Hubscher et al. | Mar 2003 | B1 |
6534324 | Zin | Mar 2003 | B1 |
6544474 | Douglas | Apr 2003 | B2 |
6548309 | Moore et al. | Apr 2003 | B1 |
6551842 | Carpenter | Apr 2003 | B1 |
6592815 | Zimmer | Jul 2003 | B1 |
6593085 | Barnett et al. | Jul 2003 | B1 |
6602719 | Carpenter | Aug 2003 | B1 |
6617116 | Guan et al. | Sep 2003 | B2 |
6623955 | Matner et al. | Sep 2003 | B2 |
6627459 | Tung et al. | Sep 2003 | B1 |
6632681 | Chu | Oct 2003 | B1 |
6645732 | Faatz et al. | Nov 2003 | B2 |
6649418 | Geisberg | Nov 2003 | B1 |
6656744 | Pronovost et al. | Dec 2003 | B2 |
6656745 | Cole | Dec 2003 | B1 |
6660469 | Wright et al. | Dec 2003 | B1 |
6663833 | Stave et al. | Dec 2003 | B1 |
6673628 | Freitag et al. | Jan 2004 | B2 |
RE38430 | Rosenstein | Feb 2004 | E |
6686167 | Bagaria | Feb 2004 | B2 |
6699722 | Bauer et al. | Mar 2004 | B2 |
6703196 | Klepp et al. | Mar 2004 | B1 |
6706539 | Nelson et al. | Mar 2004 | B2 |
6713309 | Anderson et al. | Mar 2004 | B1 |
6727073 | Moore et al. | Apr 2004 | B1 |
6737277 | Kang et al. | May 2004 | B1 |
6750031 | Ligler et al. | Jun 2004 | B1 |
6753190 | Okada et al. | Jun 2004 | B1 |
6767710 | DiNello et al. | Jul 2004 | B2 |
6767714 | Nazareth et al. | Jul 2004 | B2 |
6780651 | Douglas et al. | Aug 2004 | B2 |
6790611 | Lassen et al. | Sep 2004 | B2 |
6797481 | Ullman et al. | Sep 2004 | B1 |
6808889 | Fitzpatrick et al. | Oct 2004 | B2 |
6808937 | Ligler et al. | Oct 2004 | B2 |
6812038 | Mendel-Hartvig et al. | Nov 2004 | B1 |
6818180 | Douglas et al. | Nov 2004 | B2 |
6818455 | May et al. | Nov 2004 | B2 |
6824975 | Hubscher et al. | Nov 2004 | B2 |
6824997 | Moore et al. | Nov 2004 | B1 |
6828110 | Lee et al. | Dec 2004 | B2 |
RE38688 | Friesen et al. | Jan 2005 | E |
6844200 | Brock | Jan 2005 | B2 |
6846635 | Anderson et al. | Jan 2005 | B1 |
6849414 | Guan et al. | Feb 2005 | B2 |
6855561 | Jerome et al. | Feb 2005 | B2 |
6863866 | Kelly et al. | Mar 2005 | B2 |
6867051 | Anderson et al. | Mar 2005 | B1 |
6887701 | Anderson et al. | May 2005 | B2 |
6905835 | Sorell Gomez et al. | Jun 2005 | B2 |
6924153 | Boehringer et al. | Aug 2005 | B1 |
6927068 | Simonson et al. | Aug 2005 | B2 |
6991940 | Carroll et al. | Jan 2006 | B2 |
7018847 | Mendel-Hartvig et al. | Mar 2006 | B2 |
7045342 | Nazareth et al. | May 2006 | B2 |
7049130 | Carroll et al. | May 2006 | B2 |
7109042 | May et al. | Sep 2006 | B2 |
7189522 | Esfandiari | Mar 2007 | B2 |
7270995 | Matsushita et al. | Sep 2007 | B2 |
7682801 | Esfabdiari | Mar 2010 | B2 |
7879597 | Esfandiari | Feb 2011 | B2 |
20010012637 | Casterlin et al. | Aug 2001 | A1 |
20010026942 | Carpenter et al. | Oct 2001 | A1 |
20010026944 | Chung et al. | Oct 2001 | A1 |
20010034068 | Spivey et al. | Oct 2001 | A1 |
20010039057 | Douglas et al. | Nov 2001 | A1 |
20010048893 | Norris et al. | Dec 2001 | A1 |
20020001853 | Obremski et al. | Jan 2002 | A1 |
20020015663 | Goldstein et al. | Feb 2002 | A1 |
20020019062 | Lea et al. | Feb 2002 | A1 |
20020031839 | McNeirney et al. | Mar 2002 | A1 |
20020046614 | Alley | Apr 2002 | A1 |
20020048819 | Alley | Apr 2002 | A1 |
20020052050 | Douglas et al. | May 2002 | A1 |
20020057991 | Kelly et al. | May 2002 | A1 |
20020058330 | Carroll et al. | May 2002 | A1 |
20020110803 | Dhar et al. | Aug 2002 | A1 |
20020119497 | Wild et al. | Aug 2002 | A1 |
20020142291 | Bauer et al. | Oct 2002 | A1 |
20020155028 | Wong | Oct 2002 | A1 |
20020172937 | Dave et al. | Nov 2002 | A1 |
20020173050 | DiNello et al. | Nov 2002 | A1 |
20020192839 | Mink et al. | Dec 2002 | A1 |
20030045001 | Burgess et al. | Mar 2003 | A1 |
20030118480 | Kaylor et al. | Jun 2003 | A1 |
20030124740 | Bachand | Jul 2003 | A1 |
20030138351 | Etes et al. | Jul 2003 | A1 |
20030143639 | Matsushita et al. | Jul 2003 | A1 |
20030180967 | Shigetoh | Sep 2003 | A1 |
20040001767 | Peters et al. | Jan 2004 | A1 |
20040087036 | Chung et al. | May 2004 | A1 |
20040142495 | Hartman et al. | Jul 2004 | A1 |
20040161859 | Guo et al. | Aug 2004 | A1 |
20040184954 | Guo et al. | Sep 2004 | A1 |
20040219694 | Chittock et al. | Nov 2004 | A1 |
20040235189 | Lu | Nov 2004 | A1 |
20040241779 | Piasio et al. | Dec 2004 | A1 |
20040248322 | Charlton | Dec 2004 | A1 |
20050074900 | Morgan et al. | Apr 2005 | A1 |
20050079629 | Guo et al. | Apr 2005 | A1 |
20050112779 | Wei et al. | May 2005 | A1 |
20050112780 | Song | May 2005 | A1 |
20050112782 | Buechler | May 2005 | A1 |
20050130293 | Blatt et al. | Jun 2005 | A1 |
20050130319 | Biegelsen et al. | Jun 2005 | A1 |
20050136500 | Yang et al. | Jun 2005 | A1 |
20050142032 | Hoenes et al. | Jun 2005 | A1 |
20050164404 | Marlborugh et al. | Jul 2005 | A1 |
20050170527 | Boehringer et al. | Aug 2005 | A1 |
20050208677 | Owens et al. | Sep 2005 | A1 |
20050227371 | Gokhan | Oct 2005 | A1 |
20050244985 | Freitag et al. | Nov 2005 | A1 |
20050244986 | May et al. | Nov 2005 | A1 |
20060099719 | Curcio | May 2006 | A1 |
20060121626 | Imrich | Jun 2006 | A1 |
20060134803 | Esfandiari | Jun 2006 | A1 |
20060166374 | Hubscher | Jul 2006 | A1 |
20070020768 | Rundstrom et al. | Jan 2007 | A1 |
20070184492 | Wang et al. | Aug 2007 | A1 |
20070243630 | Boehringer et al. | Oct 2007 | A1 |
20080318341 | Esfandiari | Dec 2008 | A1 |
20090148933 | Battrell et al. | Jun 2009 | A1 |
20120003727 | Esfandiari | Jan 2012 | A1 |
Number | Date | Country |
---|---|---|
19917093 | Oct 2000 | DE |
10313158 | Oct 2004 | DE |
0299359 | Jan 1989 | EP |
1284422 | Feb 2003 | EP |
05104052 | Apr 1993 | JP |
WO8808534 | Nov 1988 | WO |
WO2004084274 | Sep 2004 | WO |
WO2005070324 | Aug 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20120208299 A1 | Aug 2012 | US |